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Letter 
 
Reverse phenotyping in patients with skin capillary malformations and mosaic GNAQ or 
GNA11 mutations defines a clinical spectrum with genotype-phenotype correlation. 
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To the Editor 
 
Post-zygotic mutations in GNAQ/GNA11 genes encoding heterotrimeric G protein alpha 
subunits account for skin mosaic conditions with vascular or pigmentary anomalies (Shirley 
et al. 2013; Thomas et al. 2016; Couto et al. 2017; Siegel et al. 2018). We sought to delineate 
the phenotype of 32 patients with skin capillary malformations (CMs) harbouring an 
activating post-zygotic mutation in GNA11 or GNAQ in affected skin. Nevus flammeus, 
ipsilateral segmental overgrowth, varicose veins and macrocephaly were associated with 
GNAQ mutations, whereas cutis marmorata, nevus anemicus, and ipsilateral hypotrophy 
were associated with GNA11 mutations. Pigmentary anomalies were only associated with 
pigment skin type. Additional extracutaneous features included ocular and neurological 
anomalies of the Sturge-Weber syndrome, varicose veins with deep vein thrombosis, and 
hypertension with renal anomalies, encompassing a wide clinical spectrum. 
 
All 32 patients (19 females, 13 males) aged 3 months to 67 years (median 14 years) were 
referred for genetic testing because of cutaneous CMs suggesting involvement of GNA11 or 
GNAQ, and were included in the Mosaic Undiagnosed Skin Traits And Related Disorders 
(M.U.S.T.A.R.D. - NCT01950975) cohort, approved by our regional institutional review board 
and ethics committee. Five patients with phakomatosis pigmentovascularis (PPV) were 
previously reported (Thomas et al. 2016). Written informed consent from all participants or 
their parents was obtained. Ultradeep next generation sequencing of the whole coding 
sequence of GNAQ/GNA11 (600 X to 6700 X) was performed on DNA from affected skin and 
venous blood on a MiSeq (Illumina®) according to standard protocol. 
Patients were phenotypically classified based on clinical charts and photographs from 
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referring clinicians, with additional data from a standardised questionnaire addressing 
vascular, pigmentary, neurological and ocular involvement, or overgrowth. Cutaneous CMs 
were subclassified as suggested by Happle: nevus flammeus (port wine stain), nevus roseus 
(pale pink nevus), cutis marmorata/reticulate CM, and nevus anemicus (Figure 1) (Happle 
2015). Patients with vascular and pigmentary manifestations were diagnosed with PPV and 
classified into one of the three types defined by Happle (Happle 2005). Patients with 
vascular anomalies and segmental asymmetry (overgrowth or hypotrophy) were assigned to 
one of the six types defined by Oduber et al (Oduber et al. 2011). Association between 
phenotypes and GNAQ or GNA11 mutations was analysed using two-tailed Fisher’s exact 
test. 
 
Most patients (n=19) carried a post zygotic p.Arg183Gln GNAQ mutation in their CMs, and 
only one had a p.Arg183Gly GNAQ mutation (Table 1 S1). Twelve patients carried a GNA11 
mutation: p.Arg183Cys (n=10), p.Arg183His (n=1), p.Gln209His (n=1). A post zygotic PIK3CA 
mutation was excluded in 9 patients – two initially referred for suspicion of macrocephaly – 
capillary malformation – polymicrogyria syndrome (MCAP, OMIM#602501), the seven others 
with a Klippel-Trénaunay syndrome (KTS). Variant allele fraction in affected tissue ranged 
from 1 % to 17 % (median = 5%). 
Cutaneous CMs (Figure 2A) involved the face in 21 patients, and multiple body segments in 
23. Nevus flammeus was associated with GNAQ rather than GNA11 mutations, yet not 
significantly (p=0.069). In contrast, nevus anemicus and cutis marmorata were associated 
with GNA11 mutations (p= 0.030 and p=0.042, respectively). Nevus roseus did not show any 
association with either GNAQ or GNA11 mutations. Nevus anemicus was always associated 
with other CMs (resulting in nevus vascularis mixtus), mainly cutis marmorata (10 patients).  
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Pigmentary anomalies associated with CMs, (Figure 2B) consisted of extensive dermal 
melanocytosis, scleral melanocytosis, or café-au-lait macules, and led to a diagnosis of PPV 
in 11 patients. They were not preferentially associated with either GNAQ or GNA11 
mutations but instead with pigment skin types III-V (11/20 patients), and were absent in skin 
types I-II (p=0.006). Similar findings had previously been reported (Polubothu and Kinsler 
2017). All PPV cesioflammea patients carried GNAQ mutations, whereas all PPV 
cesiomarmorata patients carried GNA11 mutations. No patients had PPV spilorosea. Three 
PPV patients could not be classified. 
In patients with facial CMs (Figure 2C), macrocephaly or hemifacial overgrowth were 
associated with a GNAQ mutation. Thirteen patients had Sturge-Weber syndrome, with 
seizures, brain MRI anomalies (leptomeningeal angiomatosis, cortical atrophy with 
calcifications), or glaucoma, without preferential GNAQ or GNA11 genotype. In patients with 
extra-cephalic CMs (Figure 2D), proportionate ipsilateral segmental overgrowth was found in 
50%, mainly with nevus flammeus-type CMs and GNAQ mutations. In contrast, all patients 
with ipsilateral segmental hypotrophy (inverse Klippel-Trénaunay syndrome)(Danarti et al. 
2007) carried a GNA11 mutation. Varicose veins were present in 7 patients with GNAQ 
mutations. Three of them experienced deep vein thrombosis. Most patients with 
overgrowth could be clinically classified as type 1 (CM type) or 2 (CM-venous malformation 
type), but types 3 (Klippel-Trénaunay type) and 6 (reticular CM type) were also found. Two 
patients could not be classified. 
Six patients had arterial hypertension, associated with renal artery dysplasia in two, and 
renal hypoplasia in two. No preferential association with either GNAQ or GNA11 mutations 
was found. 
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Our results suggest that clinical features in CM patients may differentiate between GNAQ 
and GNA11 mutations, although more patients need to be studied to corroborate our 
findings. A limitation to our study is the absence of information on evolution. CMs may be 
classified differently at birth than later in life, particularly cutis marmorata/reticulate CM, 
which may evolve into a homogeneous CM with time. Likewise, with age, nevus roseus may 
darken and EDM may fade away. Also, extensive skin involvement in most patients and high 
frequency of extracutaneous manifestations reflect ascertainment bias, as only severe forms 
were referred. Yet, posterior phenotyping has allowed us to better define the highly variable 
mosaic GNAQ/GNA11-related clinical spectrum. Association of overgrowth with a slow flow 
vascular anomaly can be diagnosed as KTS(Vahidnezhad et al. 2016). However, 
GNAQ/GNA11-related overgrowth, previously reported (Couto et al. 2017), was 
proportionate and milder than in PIK3CA-related KTS (Keppler-Noreuil et al. 2014; Keppler-
Noreuil et al. 2015). The term ‘‘diffuse capillary malformation with overgrowth’’ (DCMO) has 
been suggested for extensive reticular/homogeneous CMs with proportionate overgrowth 
(Lee et al. 2013), and may apply to many patients in our series. No correlation was found 
between GNAQ/GNA11 mutations and the classification of vascular anomalies associated 
with deregulated growth by Oduber et al., since our patients belonged to four of the six 
subtypes, or could not be classified at all (Oduber et al. 2011). Varicose veins and thrombosis 
may be associated with overgrowth. To our knowledge, hypertension and renal anomalies 
had not previously been reported in association with GNAQ/GNA11 mutations. They are 
reminiscent of the vascular manifestations of neurofibromatosis type I, due to mutations in a 
small G protein, and should be considered in the clinical assessment and follow-up of 
GNAQ/GNA11 patients. 
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Legends to figures. 
Figure 1. Cutaneous vascular or pigmentary phenotypes associated with GNAQ and GNA11 
mutations. (a) Patient 3886. Naevus vascularis mixtus (naevus flammeus and naevus 
anemicus; GNAQ p.Arg183Gly). (b) Patient 4396. PPV cesioflammea and naevus anemicus, 
macrocephaly, and SWS (GNAQ p.Arg183Gln). (c) Patient 1085. Naevus vascularis mixtus 
(naevus anemicus and cutis marmorata; GNA11 p.Gln209His) (d) Patient 4037. PPV 
cesiomarmorata and naevus anemicus (GNA11 p.Arg183Cys). (e) Patient 2846. Naevus 
vascularis mixtus (naevus roseus and naevus anemicus; GNA11 p.Arg183Cys). (f) Patient 
2824. Naevus flammeus and ipsilateral limb overgrowth. (GNAQ p.Arg183Gln-). (g) Patient 
4849. Naevus flammeus, overgrowth (length and girth) and varicose veins (GNAQ 
p.Arg183Gln). (h) Patient 2579 Naevus vascularis mixtus (naevus anemicus and cutis 
marmorata) with ipsilateral lower limb hypotrophy (GNA11 p.Arg183His). Patients or their 
parents consented to the publication of their image.
Figure 2. Distribution of clinical findings with respect to GNAQ and GNA11 mutations. 
(A) Types of capillary malformations. (B) Pigmentary features and PPV types. (C) Associations 
with facial capillary malformations. (D) Associations with extra-cephalic capillary 
malformations. PPV: phacomatosis pigmentovascularis ; CALMs: café-au-lait macules ; SM: 
scleral melanocytosis; EDM: extensive dermal melanocytosis ; CM : capillary malformation ; 
MRI: magnetic resonance imaging. 


Patients Gene 
Variation 
(amino acids) 
Allelic 
fraction 
(%) 
Pigment 
Skin 
type 
Cutaneous capillary 
malformation 
Overgrowth Hypotrophy 
Neurological 
anomalies 
Glaucoma 
Venous 
anomalies 
Pigmentary 
anomalies 
Other features 
PED1064 GNAQ p.(Arg183Gln) 6.0 IV 
Naevus flammeus: 
extensive, F, L ; 
anaemic naevus: F,L 
L,  
Macrocephaly 
- - + - 
EDM 
SM 
Arterial hypertension,  
renal artery dysplasia 
PED1153 GNAQ p.(Arg183Gln) 3.0 II 
Naevus flammeus: L;  
cutis marmorata: F, 
extensive 
Macrocephaly - 
Seizures,  
ID, LA,  
brain atrophy 
+ - - - 
PED1500 GNAQ p.(Arg183Gln) 5.0 IV 
Naevus flammeus: 
extensive, F , L 
Lips - ID - - EDM Dental anomalies 
PED1991 GNAQ p.(Arg183Gln) 6.5 IV 
Naevus flammeus: 
extensive, extrafacial 
L, mild - - - 
VV, partial 
agenesia 
- - 
PED2333 GNAQ p.(Arg183Gln) 3.0 III 
Naevus flammeus: 
extensive, F, L 
L, mild - 
Seizures,  
LA,  
brain atrophy 
+ 
VV, 
thrombosis 
- 
Arterial hypertension, 
Renal atrophy 
PED2355 GNAQ p.(Arg183Gln) 6.0 III 
Naevus flammeus: 
extensive F, L 
 - - - - - SM - 
PED2360 GNAQ p.(Arg183Gln) 8.0 III Naevus flammeus: LL L, mild - - - VV - - 
PED2379 GNAQ p.(Arg183Gln) 4.8 II Naevus flammeus: LL L, mild - - - 
VV, 
thrombosis 
- - 
PED2586 GNAQ p.(Arg183Gln) 10.0 III Naevus flammeus: L L, mild - - - 
VV, partial 
agenesia, 
thrombosis 
- - 
PED2613 GNAQ p.(Arg183Gln) 4.0 III 
Naevus flammeus: F, 
UL;  
cutis marmorata: LL 
L + F, mild - - - - - Scoliosis 
PED2824 GNAQ p.(Arg183Gln) 4.0 II Naevus flammeus: LL L, mild - - - - - Scoliosis 
PED3248 GNAQ p.(Arg183Gln) 7.0 V Naevus flammeus: UL UL, mild - - - - EDM - 
PED3396 GNAQ p.(Arg183Gln) 5.0 II 
Naevus flammeus: F, 
UL 
Macrocephaly - LA - - - - 
PED3886 GNAQ p.(Arg183Gln) 7.1 III 
Naevus flammeus: 
extensive F, T, L; 
anaemic naevus: T 
L, mild - - - - - - 
PED4046 GNAQ p.(Arg183Gln) 17.0 II Naevus flammeus: F F - - - - - - 
PED4110 GNAQ p.(Arg183Gln) 4.0 II 
Cutis marmorat: 
extensive F + L;  
anaemic naevus: F 
L, mild - - + - - - 
PED4396 GNAQ p.(Arg183Gln) 4.0 IV 
Naevus flammeus: F; 
naevus roseus: L; 
anaemic naevus: F 
Macrocephaly - - + - EDM - 
PED4720 GNAQ p.(Arg183Gly) 5.0 IV Naevus flammeus: F - Microcephaly Seizures, ID, LA + - - - 
PED4849 GNAQ p.(Arg183Gln) 3.8 III Naevus flammeus: L L, mild - - - 
VV, partial 
agenesia 
- Arterial hypertension 
PED4965 GNAQ p.(Arg183Gln) 6.0 II Naevus flammeus: - - - - VV - - 
mild limb 
PED1077 GNA11 p.(Arg183Cys) 4.9 II 
Cutis marmorata + 
anaemic naevus: F, L 
- L 
ID,  
LA 
- - - Iris heterochromia 
PED1085 GNA11 p.(Gln209His) 4.0 III 
Cutis marmorata + 
anaemic naevus: T 
- - - - - - 
Arterial hypertension, 
Renal artery dyslasia 
PED1494 GNA11 p.(Arg183Cys) 5.0 IV 
Naevus roseus + 
anaemic naevus: F;  
Cutis marmorata: T, L 
- F Seizures + - 
SM, self-
resoluting EDM 
Epidermal naevus 
PED2082 GNA11 p.(Arg183Cys) 5.5 III 
Naevus flammeus: F; 
naevus roseus + 
anaemic naevus: F, T, 
L 
- - LA + - Naevus spilus - 
PED2363 GNA11 p.(Arg183Cys) 3.0 II 
Naevus flammeus: F, 
L; cutis marmorata + 
anaemic naevus: T, L 
- mild LL - - - - - 
PED2579 GNA11 p.(Arg183His) 3.0 II 
Cutis marmorata + 
anaemic naevus: T, LL 
- mild LL - - - - - 
PED2846 GNA11 p.(Arg183Cys) 4.0 II 
Naevus roseus: F;   
Cutis marmorata + 
anaemic naevus: T, L 
- - - - - - - 
PED3078 GNA11 p.(Arg183Cys) 6.0 II 
Naevus flammeus: F, 
T, L 
L, mild - 
Seizures,  
LA 
brain atrophy 
- VV - 
Scoliosis, lipoma,  
Arterial hypertension, 
Renal atrophy 
PED3577 GNA11 p.(Arg183Cys) 7.1 III 
Naevus roseus + 
anaemic naevus: F;  
cutis marmorata: T, L 
- - 
Seizures,  
ID,  
LA 
+ - SM - 
PED3767 GNA11 p.(Arg183Cys) 3.7 III 
Cutis marmorata + 
anaemic naevus: LL 
- - - - - CALS - 
PED4037 GNA11 p.(Arg183Cys) 3.5 III 
Naevus roseus: F;  
cutis marmorata + 
anaemic naevus: F, T, 
L 
- - - - - EDM - 
PED4729 GNA11 p.(Arg183Cys) 14.0 NA NA LL, mild - - - - Bilateral SM - 
F: Face; L: Limbs, EDM: Extensive dermal melanocytosis; SM: Scleral melanocytosis; ID: Intellectual disability; LA: Leptomeningeal angiomatosis; VV: Varicose vein; UL: Upper Limb; LL: Lower limb; NA: Not available. 
 
Supplementary Table 1 : Genotype and phenotype from the 32 affected individuals. 
 
